Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 3 randomized, double-blind, placebo-controlled study to confirm the efficacy of a single dose of baloxavir marboxil in the prevention of influenza virus infection

Next Previous
Trial Profile

A phase 3 randomized, double-blind, placebo-controlled study to confirm the efficacy of a single dose of baloxavir marboxil in the prevention of influenza virus infection

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Baloxavir-marboxil (Primary)
  • Indications Influenza virus infections
  • Focus Registrational; Therapeutic Use
  • Acronyms BLOCKSTONE
  • Sponsors Shionogi

    • Most Recent Events

    • 02 Sep 2019 According to an Genentech media release, this study is the first to show that Xofluza is an effective preventive treatment following exposure to the flu and the company looks forward to sharing these data with health authorities.
    • 02 Sep 2019 According to an Genentech media release, full results of the study were presented as a late-breaking abstract during the OPTIONS X 2019 congress in Singapore(Abstract #11718).
    • 02 Sep 2019 Results published in the Genentech Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top